Targeting SLC1A1 can inhibit glutamine metabolism, reduce R-2-HG accumulation, and thereby suppress tumor cell proliferation while enhancing the efficacy of chemotherapy (102, 103). The gene discussed is SLC1A1; the disease is neoplasm.